Cytomegalovirus-associated allograft rejection in heart transplant patients.
about
An important role for autoimmunity in the immunopathogenesis of chronic allograft rejectionInfection in Organ Transplantation.Human Cytomegalovirus Latency: Approaching the Gordian Knot.Virus vasculopathy and stroke: an under-recognized cause and treatment target.Opportunistic infections--coming to the limits of immunosuppression?Anti-CMV-IgG positivity of donors is beneficial for alloHSCT recipients with respect to the better short-term immunological recovery and high level of CD4+CD25high lymphocytes.Cardiac allograft vasculopathy: a donor or recipient induced pathology?Cytomegalovirus infection and disease reduce 10-year cardiac allograft vasculopathy-free survival in heart transplant recipients.Cytomegalovirus infection in renal transplantation: clinical aspects, management and the perspectives.Clues to the etiology of bile duct injury in biliary atresiaCytomegalovirus infections in solid organ transplantation: a review.Defining the risks for cytomegalovirus infection and disease after solid organ transplantation.Cytomegalovirus-associated renal allograft rejection: new challenges for antiviral preventive strategies.The search for new therapies for human cytomegalovirus infections.Endothelial dysfunction and cardiac allograft vasculopathy.Treatment of cytomegalovirus infections beyond acute disease to improve human health.Interacting mechanisms in the pathogenesis of cardiac allograft vasculopathy.Recent Advances in Etiology of Biliary Atresia.HIV, highly active antiretroviral therapy and the heart: a cellular to epidemiological review.Treatment and prevention of cytomegalovirus infection in heart and lung transplantation: an update.Risk factors of cardiac allograft vasculopathy.Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation.Update on investigations pertaining to the pathogenesis of biliary atresia.Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial.
P2860
Q26827623-51A921FC-FFC7-4596-970C-D0631077CB54Q30238810-D3031044-DF09-43D8-945C-63135090AABDQ33912815-6DDEF4E6-87E5-4FE3-80BB-0A99E89EE958Q34015853-FBF006F1-E937-48A6-B881-D077CC854C5DQ35004372-B98D7E89-6549-4500-93C7-C37078FF0345Q35232833-491D28DF-C68E-4A0F-9F4E-DDC8CDC18A37Q35244151-748E848B-83B0-43FB-9A44-0746A15CBC16Q35878194-FEAA8086-7AB8-49E2-A6C8-C571603E1F7EQ37098580-85DB6432-E81D-434E-84C3-AF9D2D136D9CQ37308079-71B187C8-9C34-4A40-955F-487D3264FCB4Q37359332-2B2BEF5C-2BA5-4225-B031-0776AF9EF9D3Q37680941-1B77DCBB-B498-4655-9930-7827DB6A4F44Q37778827-D6C5AEE2-28D1-40BA-B7B8-51E93F53548DQ37811458-06568592-3B76-438F-9A42-6B0EE515B4B1Q38058477-D240B930-3F05-4E58-B493-94AA30751F6AQ38176940-94181574-1ABC-49FF-9185-D5BAAD7F4A6DQ38218005-7A4B56C6-462C-4EF5-B56B-4E0C89479419Q38245985-EB7A9EA8-9DF8-4756-8091-AE3F38F45826Q38649363-8C9C2825-4346-435E-8FF9-8139F5A81368Q38875887-1096EF3A-FF68-4D1C-9888-DFDA532AB589Q40800486-40D55746-D8AE-4112-BADC-FA205D190A80Q43523397-783079AE-148F-47FD-8DDA-FFE1CD2C5860Q50075063-2DE3D55F-D41D-41C4-AC85-164861463BB3Q51067478-35DC0E57-3904-4315-8686-28FBE884C70D
P2860
Cytomegalovirus-associated allograft rejection in heart transplant patients.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Cytomegalovirus-associated allograft rejection in heart transplant patients.
@en
type
label
Cytomegalovirus-associated allograft rejection in heart transplant patients.
@en
prefLabel
Cytomegalovirus-associated allograft rejection in heart transplant patients.
@en
P1476
Cytomegalovirus-associated allograft rejection in heart transplant patients.
@en
P2093
Hannah A Valantine
Luciano Potena
P304
P356
10.1097/QCO.0B013E328259C33B
P577
2007-08-01T00:00:00Z